IBRX Q4 2018 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7,000-41.7% YoY

Gross Profit

$7,000100.0% margin

Operating Income

-$17M-247471.4% margin

Net Income

-$17M-247714.3% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

-77.4%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$16M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$182M

Total Liabilities

$36M

Stockholders' Equity

$146M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7,000	$12,000	-41.7%
Gross Profit	$7,000	$12,000	-41.7%
Operating Income	-$17M	-$25M	+29.7%
Net Income	-$17M	-$24M	+29.2%